Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control
George Duke, Department of Defense (W81XWH-21-1-0377), NIH/NIGMS (GM147497), American Cancer Society (RSG-22-071-01-TBE), NIH (1R01 CA255515-01A1), NIH/NCI (P30CA013696 and P30CA016056).
Authors
- Viraj R. Sanghvi (ORCID: https://orcid.org/0000-0001-6526-7820)
- Spencer R. Rosario (ORCID: https://orcid.org/0000-0002-2626-9257)
- Randall J. Smith (ORCID: https://orcid.org/0000-0001-8114-3086)
- Bailey G. Fitzgerald (ORCID: https://orcid.org/0000-0002-5566-5953)
- Yeshwanth Vedire (ORCID: https://orcid.org/0000-0003-3611-2592)
- Sukumar Kalvapudi (ORCID: https://orcid.org/0000-0003-0233-4648)
- Deschana Washington
- Meera Bhatia
- Sai Yendamuri (ORCID: https://orcid.org/0000-0001-6654-3487)
- Akhil Goud Pachimatla (ORCID: https://orcid.org/0000-0002-0276-6769)
- Kalyan Ratnakaram
- Joseph Barbi (ORCID: https://orcid.org/0000-0002-5632-0885)
- Hua-Hsin Hsiao
- Joyce Ogidigo
- Robert Vethanayagam rr
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Columbia University Irving Medical Center (US)
Publication Details
- Journal
- JCI Insight
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1172/jci.insight.195484
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute